Not finding it? Sign in to also search OpenAlex live.
-
Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).2023 Journal of Clinical Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
George K.K. Lau, Bruno Sangro, Oxana Crysler, Wattana Sukeepaisarnjaroen, Oleg Nikolaevich Lipatov, Manabu Morimoto, +12 more
8citations -
Mapping the blood vasculature in an intact human kidney using hierarchical phase-contrast tomography2023 bioRxiv (Cold Spring Harbor Laboratory) preprint Physics and Astronomy Digital Holography and Microscopy Open access
Shahrokh Rahmani, Daniyal J. Jafree, Peter David Lee, Paul Tafforeau, Joseph Brunet, Sonal Nandanwar, +7 more
7citations -
Patient-Reported Outcomes (PROs) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 and COMMODORE 1 Trials
Jens Panse, Jaroslav Čermák, Olena Kyselova, Akihiko Gotoh, Fahri Şahin, Hubert Schrezenmeier, +3 more
4citations -
Characteristics of Patients With Asymptomatic Atrial Fibrillation and Ischemic Stroke—Insights From the GLORIA‐AF Registry (Phase 2)2024 Pacing and Clinical Electrophysiology article Medicine Atrial Fibrillation Management and Outcomes Open access
Tobias Heer, Uwe Zeymer, Christopher Jan Schwarzbach, Karl-Heinz Seidl, Ursula Rauch‐Kröhnert, Sabrina Vogel Marler, +5 more
2citations -
MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study2020 Journal of the Endocrine Society article Medicine Pituitary Gland Disorders and Treatments Open access
Lisa B. Nachtigall, Susan Leanne Samson, Maria Fleseriu, Marek Bolanowski, William Henry Ludlam, Gary Patou, +7 more
0citations -
Rhythm Control in Patients With Recently Diagnosed Atrial Fibrillation: Findings From the GLORIA‐AF Registry Phase III2026 Journal of the American Heart Association article Medicine Atrial Fibrillation Management and Outcomes Open access
Bernadette Corica, Giulio Francesco Romiti, Marco Proietti, Davide Antonio Mei, Giuseppe Boriani, Brian Olshansky, +3 more
0citations -
eGFR Decline in Patients with IgA Nephropathy Treated with Nefecon or Placebo: Results from the 2-Year NefIgArd Phase 3 Trial2023 Journal of the American Society of Nephrology conference-abstract Medicine Renal Diseases and Glomerulopathies
Richard A. Lafayette, Jens Halkjaer Kristensen, Andrew M. Stone, Jürgen Floege, Vladimı́r Tesař, Hernán Trimarchi, +6 more
0citations -
SCOPES-II: short course of preoperative radiotherapy in head and neck, trunk and extremity soft tissue sarcomas – study protocol for a second randomised phase II clinical trial
Geraldien Florine Foppele, Marta F. Fiocco, Olga Husson, Astrid Kramer, Valesca P. Retèl, Vincent van der Noort, +11 more
0citations -
Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors2025 Cancer Research Communications article Medicine Lung Cancer Treatments and Mutations Open access cited by 1 patent
Kristoffer Staal Rohrberg, Juanita Suzanne Lopez, Mohammed M. Milhem, Christian U. Blank, Irene L. M. Reijers, Fiona C. Thistlethwaite, +34 more
5citations -
Analysis of Drivability Influence on Tailpipe Emissions in Early Stages of a Vehicle Development Program by Means of Engine-in-the-Loop Test Benches2020 SAE technical papers on CD-ROM/SAE technical paper series conference-paper Engineering Vehicle emissions and performance
Christian Heusch, Daniel Guse, Frank Dorscheidt, Timm Fahrbach, Stefan Pischinger, Stefan Tegelkamp, +3 more
9citations -
Simultaneous retrieval of orbital phase resolved JWST/MIRI emission spectra of the hot Jupiter WASP-43b: evidence of water, ammonia, and carbon monoxide2024 Monthly Notices of the Royal Astronomical Society article Physics and Astronomy Stellar, planetary, and galactic studies Open access
Jingxuan Yang, Mark Hammond, Anjali A. A. Piette, Jasmina Blecic, Taylor James Bell, P. G. J. Irwin, +11 more
14citations -
Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study
Morag Griffin, Richard J. Kelly, Mathilde Gavillet, Petra Muus, Britta Hoechsmann, W. Jason Cummings, +4 more
4citations -
MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
2citations -
Dose escalations in phase I studies: Feasibility of interpreting blinded pharmacodynamic data2022 British Journal of Clinical Pharmacology article Mathematics Statistical Methods in Clinical Trials Open access
Gerardus J. Hassing, Michiel Joost van Esdonk, Gerard J. P. van Westen, Adam F. Cohen, Jacobus Burggraaf, Pim Gal
2citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
1citations -
P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +11 more
1citations -
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial
Andrew Paul Cope, Marianna Jasenecova, Joana Carvalho Vasconcelos, Andrew D. Filer, Karim Raza, Sumera Qureshi, +61 more
182citations -
Real‐world outcomes of advanced melanoma patients not represented in phase III trials2020 International Journal of Cancer article Medicine Cutaneous Melanoma Detection and Management Open access
Michiel C.T. van Zeijl, Rawa Kamaran Ismail, Liesbeth C. de Wreede, Alfonsus Johannes Maria van den Eertwegh, Anthonius de Boer, Maaike van Dartel, +15 more
39citations -
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
Pieter Sonneveld, Meletios Athanasios Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, +37 more
18citations